CN104395343A - 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案 - Google Patents
抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案 Download PDFInfo
- Publication number
- CN104395343A CN104395343A CN201380035806.8A CN201380035806A CN104395343A CN 104395343 A CN104395343 A CN 104395343A CN 201380035806 A CN201380035806 A CN 201380035806A CN 104395343 A CN104395343 A CN 104395343A
- Authority
- CN
- China
- Prior art keywords
- antibody
- nogo
- limited
- days
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 41
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 19
- 102000010410 Nogo Proteins Human genes 0.000 claims description 72
- 108010077641 Nogo Proteins Proteins 0.000 claims description 72
- 239000003814 drug Substances 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000012423 maintenance Methods 0.000 claims description 9
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 7
- 229960004181 riluzole Drugs 0.000 claims description 7
- FASDKYOPVNHBLU-SSDOTTSWSA-N dexpramipexole Chemical compound C1[C@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-SSDOTTSWSA-N 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 229950004920 dexpramipexole Drugs 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000021642 Muscular disease Diseases 0.000 claims description 3
- 201000009623 Myopathy Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000020339 Spinal injury Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 description 20
- 210000003205 muscle Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000000975 dye Substances 0.000 description 11
- 230000002265 prevention Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 108010083379 Sarcoglycans Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000019344 Gamma-sarcoglycan Human genes 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000000518 sarcolemma Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229950004608 talampanel Drugs 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000002594 corticospinal effect Effects 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003961 neuronal insult Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 102100029831 Reticulon-4 Human genes 0.000 description 2
- 101710122685 Reticulon-4 Proteins 0.000 description 2
- 102000006308 Sarcoglycans Human genes 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- -1 2,3-benzodiazepine compound Chemical class 0.000 description 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
- 239000000775 AMPA receptor antagonist Substances 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
- 101100004280 Caenorhabditis elegans best-2 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000669618 Nothes Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QNTASHOAVRSLMD-FCARAQADSA-N olesoxime Chemical group C1CC2=C\C(=N/O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNTASHOAVRSLMD-FCARAQADSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668134P | 2012-07-05 | 2012-07-05 | |
| US61/668134 | 2012-07-05 | ||
| PCT/EP2013/064063 WO2014006105A1 (en) | 2012-07-05 | 2013-07-03 | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104395343A true CN104395343A (zh) | 2015-03-04 |
Family
ID=48741180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380035806.8A Pending CN104395343A (zh) | 2012-07-05 | 2013-07-03 | 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案 |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102279751B1 (ko) * | 2019-06-28 | 2021-07-21 | 경북대학교 산학협력단 | 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법 |
| KR102409771B1 (ko) * | 2020-06-17 | 2022-06-16 | 경북대학교 산학협력단 | Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| DE10336350B4 (de) | 2003-08-08 | 2007-10-31 | Westfalia Separator Ag | Vollmantel-Schneckenzentrifuge, mit Schälscheibe |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| DK1711530T3 (da) | 2003-12-22 | 2009-12-14 | Glaxo Group Ltd | Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| MY149546A (en) | 2007-11-02 | 2013-09-13 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use tereof |
| JP2011527317A (ja) | 2008-07-11 | 2011-10-27 | グラクソ グループ リミテッド | Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療 |
-
2013
- 2013-07-03 KR KR20157003097A patent/KR20150036398A/ko not_active Withdrawn
- 2013-07-03 BR BR112014032987A patent/BR112014032987A2/pt not_active IP Right Cessation
- 2013-07-03 WO PCT/EP2013/064063 patent/WO2014006105A1/en active Application Filing
- 2013-07-03 AU AU2013285493A patent/AU2013285493A1/en not_active Abandoned
- 2013-07-03 CA CA2876284A patent/CA2876284A1/en not_active Abandoned
- 2013-07-03 CN CN201380035806.8A patent/CN104395343A/zh active Pending
- 2013-07-03 JP JP2015519214A patent/JP2015521992A/ja not_active Withdrawn
- 2013-07-03 IN IN2952KON2014 patent/IN2014KN02952A/en unknown
- 2013-07-03 RU RU2014150265A patent/RU2014150265A/ru not_active Application Discontinuation
- 2013-07-03 EP EP13732986.8A patent/EP2870177A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013285493A1 (en) | 2015-01-22 |
| RU2014150265A (ru) | 2016-08-27 |
| IN2014KN02952A (enrdf_load_stackoverflow) | 2015-05-08 |
| WO2014006105A1 (en) | 2014-01-09 |
| JP2015521992A (ja) | 2015-08-03 |
| CA2876284A1 (en) | 2014-01-09 |
| EP2870177A1 (en) | 2015-05-13 |
| BR112014032987A2 (pt) | 2017-06-27 |
| KR20150036398A (ko) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7785587B2 (en) | Therapeutic methods for muscular or neuromuscular disorders | |
| TWI831764B (zh) | 眼科疾病之治療 | |
| CN101653604A (zh) | 抗ngf抗体用于治疗各种疾病 | |
| US20210277111A1 (en) | Lingo-1 antagonists and uses for treatment of demyelinating disorders | |
| KR20110097772A (ko) | 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제 | |
| CN102936287A (zh) | 能够特异性结合Aβ 寡聚体的抗体及其应用 | |
| JP2024042116A (ja) | コネキシン４３抗体およびその使用 | |
| CN105592861A (zh) | 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途 | |
| ES2534646T3 (es) | Anticuerpos anti-hepsina y métodos de uso de los mismos | |
| CN104395343A (zh) | 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案 | |
| CA3030745A1 (en) | Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders | |
| TWI807338B (zh) | 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途 | |
| US20170233467A1 (en) | Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies | |
| JP6683602B2 (ja) | ヒトｃｓｆの毒性を測定する方法 | |
| TW202233676A (zh) | 使用抗ｃｄ１９抗體治療自體免疫性疾病 | |
| US20250002569A1 (en) | Method of treating osteoarthritis | |
| US20250243269A1 (en) | Anti-fsh antibodies for neurodegenerative diseases | |
| CN117440827A (zh) | 使用抗cd19抗体治疗重症肌无力 | |
| WO2024104409A1 (zh) | 一种含抗rankl-ngf双特异性抗体的药物组合物 | |
| NZ540879A (en) | Methods for treating taxol-induced sensory neuropathy | |
| HK1196272A (en) | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150304 |
|
| WD01 | Invention patent application deemed withdrawn after publication |